Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $95

Benzinga Newsdesk www.benzinga.com Positive 80.5%

Neg 0% Neu 0% Pos 80.5%

Barclays analyst Gena Wang maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $87 to $95.